BridgeBio Pharma (BBIO) was upgraded by Royal Bank Of Canada to "moderate buy".
Assessing BridgeBio Pharma (BBIO) Valuation After Recent Share Price Strength And Late Stage Pipeline Focus [Yahoo! Finance]
BridgeBio Pharma (BBIO) is now covered by Royal Bank Of Canada. They set an "outperform" rating and a $100.00 price target on the stock.
Mizuho Lifts PT on BridgeBio Pharma (BBIO) to $106 From $91 – Here's Why [Yahoo! Finance]
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54